巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Corvus Pharmaceuticals

CRVS
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Corvus Pharmaceuticals - 延遲價格・最後更新於 14/01 12:14
最高位
2.250
最低位
2.160
開市價
--
前收市價
2.190
成交量(千)
15.75
成交額(百萬)
0.21
買入
--
賣出
--
每手股數
--
市值(百萬)
104.73
市盈率
25.000
息率
--
差價
--
52週高低
9.540 - 1.860
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Corvus Pharmaceuticals
證券代碼
CRVS.US
所屬板塊
Biotechnology
公司業務
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
發行量
38309551
公司總部
863 Mitten Road, Suite 102
公司網址
https://www.corvuspharma.com
公司電郵
llea@corvuspharma.com
公司電話
+1 650 900-4520
暫無內容

關於

Corvus Pharmaceuticals(CRVS.US)所屬的行業板塊為Biotechnology。
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.
詳細公司背景可參考: https://www.corvuspharma.com